Tectonic Advisors LLC purchases 9,630 shares of HealthEquity, Inc. $HQY. October 24, 2026 Key points. * Tectonic Advisors increased its HealthEquity stake by 9.6% in the third quarter, purchasing 9,630 shares and bringing its holdings to 109,953 shares valued at approximately $9.7 million. Institutional investors collectively own 99.55% of the company. * HealthEquity reported quarterly EPS of $1.24, exceeding estimates by $0.05, while revenue reached $350.73 million, up 95.5% year over year. Shares recently traded at $103.97, near their 52-week high of $107.62. * Analyst sentiment remains favorable, with a consensus rating of "Moderate Buy" and an average price target of $113.53; several firms maintain buy or outperform ratings, though one analyst rates the stock a sell. * Is HealthEquity on your watchlist? MarketBeat All Access adds unlimited watchlist stocks and real-time alerts for $149 a year, a rate that never goes up while you are a member. Tectonic Advisors LLC grew its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 9.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,953 shares of the company's stock after purchasing an additional 9,630 shares during the period. Tectonic Advisors LLC owned about 0.13% of HealthEquity worth $9,726,000 at the end of the most recent reporting period. Other institutional investors and hedge funds also recently made changes to their positions in the company. Root Financial Partners LLC purchased a new position in HealthEquity during the third quarter worth about $58,000. Integrated Advisors Network LLC bought a new stake in HealthEquity in the 3rd quarter worth about $323,000. Abel Hall LLC grew its position in HealthEquity by 3.8% in the 3rd quarter. Abel Hall LLC now owns 6,736 shares of the company's stock worth $596,000 after purchasing an additional 247 shares in the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in HealthEquity in the 3rd quarter valued at about $604,000. Finally, Assenagon Asset Management S.A. increased its stake in HealthEquity by 54.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 32,776 shares of the company's stock valued at $2,899,000 after buying an additional 11,561 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock. HealthEquity stock performance. Shares of HQY stock traded up $3.00 on Friday, hitting $103.97. 1,020,236 shares of the stock were exchanged, compared to its average volume of 844,142. The firm's 50 day moving average is $95.36 and its two-hundred day moving average is $91.92. HealthEquity, Inc. has a one year low of $72.76 and a one year high of $107.62. The firm has a market capitalization of $8.60 billion, a PE ratio of 37.53, a P/E/G ratio of 1.59 and a beta of 0.24. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.05. The company had revenue of $350.73 million for the quarter, compared to analyst estimates of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company's revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts expect that HealthEquity, Inc. will post 3.93 earnings per share for the current fiscal year. Analyst upgrades and downgrades. Several research firms have commented on HQY. BTIG Research reissued a "buy" rating and set a $115.00 target price on shares of HealthEquity in a research report on Friday, August 28th. Citigroup reaffirmed a "market outperform" rating on shares of HealthEquity in a report on Friday, August 28th. Wall Street Zen raised HealthEquity from a "hold" rating to a "buy" rating in a research report on Saturday, October 10th. Telsey Advisory Group set a $111.00 price target on HealthEquity in a report on Friday, August 28th. Finally, Barclays boosted their price objective on HealthEquity from $110.00 to $115.00 and gave the stock an "overweight" rating in a research report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $113.53. Discover more MarketBeat All Access MarketBeat Research Tools Insider transactions at HealthEquity. In other HealthEquity news, Director Adrian Dillon sold 7,632 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the sale, the director owned 62,395 shares in the company, valued at $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.60% of the stock is owned by insiders. HealthEquity company profile. HealthEquity, Inc provides technology-enabled benefits administration and financial services that help employers and individuals manage tax-advantaged healthcare accounts. The company's offerings include health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other consumer-directed benefits. In addition to account administration, HealthEquity provides payment cards, investment options for eligible account holders, employee engagement tools, and digital platforms for managing healthcare benefits. Further reading. Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider HealthEquity, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list. While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat

HealthEquity appoints Moody's CFO Noémie Heuland to board of directors. DRAPER, Utah, Sept. 30, 2026 (GLOBE NEWSWIRE) - HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that Noémie Heuland, Chief Financial Officer of Moody's Corporation (NYSE: MCO), has been elected to its board of directors (the "Board") effective Sept. 24, 2026. Heuland will also serve on the Audit and Risk Committee and Cybersecurity and Technology Committee of the Board. Her appointment expands the Board to 11 directors, nine of whom are independent. "Noémie has built her career at the intersection of finance and technology, with deep experience leading through periods of growth and change," said Robert Selander, Chairman of the Board. "Her financial and strategic perspective will be valuable as we continue to scale HealthEquity, invest for the future and navigate the opportunities that come with our next phase of growth." "HealthEquity has built a strong business grounded in an important mission: helping people better manage and pay for healthcare," said Heuland. "I look forward to contributing my experience as the Company continues to grow, innovate, and create value for its members, clients and shareholders." Heuland has served as Chief Financial Officer of Moody's since April 2024. Before becoming CFO of Moody's, Heuland was the Chief Financial Officer at Dayforce, Inc. from October 2020 to February 2024. Before joining Dayforce, Heuland spent 12 years working for SAP in finance leadership roles. Heuland holds an M.S. in Finance and Accounting from Nantes Business School of Management, now known as Audencia. Ms. Heuland is a Certified Public Accountant. About HealthEquity HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for nearly 18 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.